Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts

Experimental Hematology

Volumn 32, Issue 4, 2004, Pages 351-359

  Doran, Patrick M ^a   Turner, Russell T ^a   Chen, David ^b   Facteau, Suzanne M ^a   Ludvigson, Jill M ^a   Khosla, Sundeep ^a   Riggs, B Lawrence ^a   Russell, Stephen J ^a  

^a MAYO CLINIC   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; LENTIVIRUS VECTOR; OSTEOPROTEGERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DISEASE; CONTROLLED STUDY; DISEASE COURSE; EMBRYO; EXPERIMENTAL MODEL; FEMALE; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; KIDNEY CELL; MARKER GENE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; RADIOGRAPHY; TUMOR XENOGRAFT; VIRUS REPLICATION;

ANIMALS; BONE DENSITY; CELL LINE, TUMOR; DNA, ANTISENSE; DNA, RECOMBINANT; GENE THERAPY; GENETIC VECTORS; GLYCOPROTEINS; LAC OPERON; LENTIVIRUS; MICE; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; OSTEOCLASTS; OSTEOLYSIS; OSTEOPROTEGERIN; PILOT PROJECTS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MURINAE;

EID: 1642634597     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2004.01.006     Document Type: Article

References (60)

1. Roodman G.D. Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer. 80:1997;1557-1563.
2. Foerster J., Paraskevas F. Multiple myeloma. Lee G.R., Foerster J. Wintrobe's Clinical Hematology. 1999;2631-2680 Williams & Wilkins, Baltimore, MD.
3. Valentin-Opran A., Charhon S.A., Meunier P.J., Edouard C.M., Arlot M.E. Quantitative histology of myeloma-induced bone changes. Br J Haematol. 52:1982;601-610.
4. Bataille R., Chappard D., Klein B. Mechanisms of bone lesions in multiple myeloma. Hematol Oncol Clin North Am. 6:1992;285-295.
5. Taube T., Beneton M.N., McCloskey E.V., Rogers S., Greaves M., Kanis J.A. Abnormal bone remodeling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol. 49:1992;192-198.
6. Berenson J.R., Lichtenstein A., Porter L., et al., Myeloma Aredia Study Group. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 334:1996;529-530.
7. Cozzolino F., Torcia M., Aldinucci D., et al. Production of interleukin-1 by bone marrow myeloma cells. Blood. 74:1989;380-387.
8. Kawano M., Yamamoto I., Iwato K., et al. Interleukin-1 β rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma. Blood. 73:1989;1646-1649.
9. Lichtenstein A., Berenson J.R., Norman D., et al. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood. 74:1989;1266-1273.
10. Klein B., Zhang X.G., Jourdan M., Portier M., Bataille R. Interleukin-6 is a major myeloma cell growth factor in vitro and in vivo especially in patients with terminal disease. Curr Top Microbiol Immunol. 166:1990;23-31.
11. Caligaris-Cappio F., Bergui L., Gregoretti M.G., et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood. 77:1991;2688-2693.
12. Garrett I.R., Durie B.G., Nedwin G.E. Production of lymphotoxin, a bone resorbing cytokine, by cultured human myeloma cells. N Engl J Med. 317:1987;526-532.
13. Mundy G.R. Hypercalcemia of malignancy revisited. J Clin Invest. 82:1988;1-6.
14. Mundy G.R., Bertolini D.R. Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol. 13:1986;291-299.
15. Kodama H., Nose M., Niida S., Yamasaki A. Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J Exp Med. 173:1991;1291-1294.
16. Borset M., Hjorth-Hansen H., Seidel C., Sundan A., Waage A. Hepatocyte growth factor and its receptor c-Met in multiple myeloma. Blood. 88:1996;3998-4004.
17. Borset M., Lien E., Espevik T., Helseth E., Waage A., Sundan A. Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-Met in human myeloma cell lines. J Biol Chem. 271:1996;24655-24661.
18. Choi S.J., Cruz J.C., Craig F., et al. Macrophage inflammatory protein 1-α is a potential osteoclast stimulatory factor in multiple myeloma. Blood. 96:2000;671-675.
19. Sordillo E.M., Wong B.R., Deng F.L., et al. Multiple myeloma disrupts the TRANCE/OPG cytokine axis. [abstract] Blood. 96:2000;549a.
20. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:1998;165-176.
21. Yasuda H., Shima N., Nakagawa N., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 95:1998;3597-3602.
22. Quinn J.M.W., Elliott J., Gillespie M.T., Martin T.J. A combination of osteoclast differentiation factor and macrophage colony-stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology. 139:1998;4424-4427.
23. Matsuzaki K., Udagawa N., Takahashi N., et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun. 246:1998;199-204.
24. Fuller K., Wong B., Fox S., Choi Y., Chambers T.J. Trance is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med. 188:1998;997-1001.
25. Burgess T.L., Qian Y., Kaufman S., et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol. 145:1999;527-538.
26. Kong Y.-Y., Yoshida H., Sarosi I., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 397:1999;315-323.
27. Tsuda E., Goto M., Mochizuki S., et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun. 324:1997;137-142.
28. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 89:1997;309-319.
29. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Boyle W.J., Riggs B.L. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res. 15:2000;2-12.
30. Yasuda H., Shima N., Nakagawa N., et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 39:1998;1329-1337.
31. Mizuno A., Murakami A., Nakagawa N., et al. Structure of the mouse osteoclastogenesis inhibitory factor/osteoprotegerin gene and its expression in embryogenesis. Gene. 215:1998;339-343.
32. Miyamoto A., Kunisada T., Hemmi H., et al. Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts. Biochem Biophys Res Commun. 242:1998;703-709.
33. Emery J.G., McDonnell P., Brigham Burke M., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 273:1998;14363-14367.
34. Lum L., Wong B.R., Josien R., et al. Evidence for a role of a tumor necrosis factor-α (TNF-α)-converting enzyme-like protease in shedding TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem. 274:1999;13613-13618.
35. Kwon B.S., Wang S., Udagawa N., et al. TR1, a new member of the tumor necrosis receptor family, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J. 12:1998;845-854.
36. Hakeda Y., Kobayashi Y., Yamaguchi K., et al. Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. Biochem Biophys Res Commun. 251:1998;796-801.
37. Akatsu T., Murakami T., Nishikawa M., et al. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclasts. Biochem Biophys Res Commun. 250:1998;229-234.
38. Giuliani N., Bataille R., Mancini C., Lazzaretti M., Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood. 98:2001;3527-3533.
39. Altamirano C.V., Ma H.J., Parker K.M., et al. RANKL is expressed in malignant multiple myeloma (MM) cell lines. [abstract] Blood. 96:2000;365a.
40. Shipman C.M., Holen I., Lippitt J.M., Vandenberghe E., Croucher P.I. Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL. [abstract] Blood. 96:2000;360a. Abstract 1552.
41. Seidel C., Hjertner O., Abildgaard N., et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood. 98:2001;2269-2271.
42. Borset M., Hjertner O., Yaccoby S., Epstein J., Sanderson R.D. Sundecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood. 96:2000;2528-2536.
43. Tricot G. New insights into the role of microenvironment in multiple myeloma. Lancet. 355:2000;248-250.
44. Hofbauer L.C., Gori F., Riggs B.L., et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 140:1999;4382-4389.
45. Vidal N.O.A., Brändtröm H., Jonsson K.B., Ohlsson C. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: downregulation by glucocorticoids. J Endcorinol. 159:1998;191-195.
46. Tomoyasu A., Goto M., Fujise N., et al. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. Biochem Biophys Res Commun. 245:1998;382-387.
47. Burk K.H., Drewinko B., Trujillo J.M., Ahearn M.J. Establishment of human plasma cell line in vitro. Cancer Res. 38:1978;2508-2513.
48. Drewinko B., Mars W., Minowada J., Burk K.H., Trujillo J.M. Arh-77, an established human IgG-producing myeloma cell line I. Morphology, B-cell phenotypic marker profile, and expression of Epstein-Barr virus. Cancer. 54:1984;1883-1892.
49. Drewinko B., Mars W., Stragand J.J., et al. ARH-77, an established human IgG-producing myeloma cell line II. Growth kinetics, clonogenic capacity, chalone production, xenogeneic transplantations, and response to melphalan. Cancer. 54:1984;1893-1903.
50. Tong A.W., Huang Y.-W., Zhang B.-Q., Netto G., Vitetta E.S., Stone M.J. Heterotransplantation of human multiple myeloma cell lines in severe combined immunodeficiency (SCID) mice. Anticancer Res. 13:1993;593-598.
51. Huang Y.-W., Richardson J.A., Tong A.W., Zhang B.-Q., Stone M.J., Vitetta E.S. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. Cancer Res. 53:1993;1392-1396.
52. Alsina M., Boyce B., Devlin R.D., et al. Development of an in vivo model of human multiple myeloma bone disease. Blood. 87:1996;1495-1501.
53. Naldini L., Blomer U., Gage F.H., Trono D., Verma I. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA. 93:1996;11382-11388.
54. Zufferey R., Nagy D., Mandel R.J., Naldini L., Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol. 15:1997;871-875.
55. v). Cancer Res. 52:1992;2304-2309.
56. Doran P.M., Chen D., Khosla S., Riggs B.L., Russell S.J. OPG gene transfer to control myelomatous skeletal disease in the ARH-77 SCID mouse model. [abstract] Blood. 96:2000;362a.
57. 2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun. 246:1998;337-341.
58. Kobayashi K., Takahashi N., Jimi E., et al. Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med. 191:2000;275-285.
59. Gooding R.P., Bybee A., Cooke F., et al. Phenotypic and molecular analysis of six human cell lines derived from patients with plasma cell dyscrasia. Br J Haematol. 106:1999;669-681.
60. Croucher P.I., Shipman C.M., Lippitt J., et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood. 98:2001;3534-3540.